Pharmagreen Biotech Inc. (PHBI) Stock Price & Analysis
Pharmagreen Biotech Inc. (PHBI) fell 5.56% to USD 0 as of June 10, 2026 at 10:10 UTC, according to Nexqual real-time market data.
PHBI last closed at USD 0; the session ranged USD 0–0 on volume of 42,537 shares. Market capitalization is $587,643, with a 52-week range of USD 0–0 (OID). Source: Nexqual, June 10, 2026 at 10:10 UTC.
Key Statistics (as of June 10, 2026 at 10:10 UTC)
| Price | USD 0 |
|---|---|
| Change | ▼ 5.56% (down) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 42,537 shares |
| Market Cap | $587,643 |
| Exchange | OID |
Technical Analysis (PHBI)
Nexqual's technical model rates PHBI "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 10:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.13 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (PHBI)
Wall Street analysts rate PHBI "None", per Nexqual as of June 10, 2026 at 10:10 UTC.
| Consensus Rating | None |
|---|
Earnings (PHBI)
Source: Nexqual, June 10, 2026 at 10:10 UTC.
Financials & Fundamentals (PHBI)
| Total Revenue | $3,002 |
|---|---|
| Revenue Growth (YoY) | -33.00% |
| Gross Margin | +44.90% |
| Operating Margin | -7420.17% |
| Profit Margin | +0.00% |
| Current Ratio | 0.04 |
| Total Cash | $906 |
| Total Debt | $352,411 |
| Free Cash Flow | $-161,086 |
Source: Nexqual, June 10, 2026 at 10:10 UTC.
Financial Health Score (PHBI)
Nexqual rates Pharmagreen Biotech Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:10 UTC.
| Growth | Critical — Revenue -33% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $906 cash, no debt |
| Cash Flow | Weak — FCF negative: -$161K, burning cash |
| Efficiency | Mixed — No data |
Ownership (PHBI)
| Insider Ownership | +12.77% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 691.35M |
| Float | 625.17M |
Source: Nexqual, June 10, 2026 at 10:10 UTC.
Leadership (PHBI)
Pharmagreen Biotech Inc. is led by Peter Wojcik B.A. (age 53), President, CEO, Secretary, Treasurer & Director, per Nexqual as of June 10, 2026 at 10:10 UTC.
| President, CEO, Secretary, Treasurer & Director | Peter Wojcik B.A. (age 53) |
|---|---|
| CFO & Principal Accounting Officer | Terry Kwan B.Com., C.A. (age 77) |
From Pharmagreen Biotech Inc.'s Latest SEC 10-K Filing (filed 2023-01-17)
Partnerships
- The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction.
- As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.   On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WDLF | Decentral Life, Inc. | USD 0 | ▲ 0% |
| HBRM | Herborium Group, Inc. | USD 0 | ▲ 0% |
| BEGI | BlackStar Enterprise Group, Inc | USD 0 | ▲ 0% |
| VDRM | ViaDerma, Inc. | USD 0 | ▲ 0% |
| GTLL | Global Technologies, Ltd. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:10 UTC. This page is informational and not investment advice.